Suchergebnisse - "Zambelli, Alberto"

PubPharm (14)

1

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)

enthalten in: Journal for immunotherapy of cancer | 2023

von Pellegrino, B. | Tommasi, C. | Serra, O. | +21

2

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy

enthalten in: Breast (Edinburgh, Scotland) | 2023

von Zambelli, A. | Cazzaniga, M. | La Verde, N. | +7

3

Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer : A Consensus Paper

enthalten in: Clinical breast cancer | 2023

von Garutti, M. | Cucciniello, L. | Arpino, G. | +7

4

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortés, J. | Kim, S. | Chung, W. | +122

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361895

5

Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY : a GRADE analysis

enthalten in: Journal of comparative effectiveness research | 2020

von Zambelli, A. | Pappagallo, G. | Marchetti, P.

6

T-DM1 and brain metastases : Clinical outcome in HER2-positive metastatic breast cancer

enthalten in: Breast (Edinburgh, Scotland) | 2018

von Fabi, A. | Alesini, D. | Valle, E. | +27

7

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients : does pretreatment with pertuzumab matter?

enthalten in: Future oncology (London, England) | 2017

von Fabi, A. | Giannarelli, D. | Moscetti, L. | +16

8

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer : Results from the Italian Retrospective Multicenter HERLAPAC Study

enthalten in: PloS one | 2016

von Gori, S. | Inno, A. | Rossi, V. | +18

9

Trastuzumab for HER2+ metastatic breast cancer in clinical practice : Cardiotoxicity and overall survival

enthalten in: European journal of cancer (Oxford, England : 1990) | 2016

von Rossi, M. | Carioli, G. | Bonifazi, M. | +8

10

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting : a controlled cohort study

enthalten in: The oncologist | 2014

von Negri, E. | Zambelli, A. | Franchi, M. | +6